- Previous Close
0.2430 - Open
0.2435 - Bid 0.2820 x --
- Ask 0.3570 x --
- Day's Range
0.2435 - 0.2495 - 52 Week Range
0.2430 - 0.8600 - Volume
200 - Avg. Volume
0 - Market Cap (intraday)
22.778M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date Aug 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.
www.intervacc.seRecent News: 2E9.F
Performance Overview: 2E9.F
Trailing total returns as of 6/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2E9.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2E9.F
Valuation Measures
Market Cap
22.18M
Enterprise Value
14.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
25.16
Price/Book (mrq)
0.94
Enterprise Value/Revenue
18.12
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.02%
Return on Equity (ttm)
-45.35%
Revenue (ttm)
8.94M
Net Income Avi to Common (ttm)
-102.77M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
71.88M
Total Debt/Equity (mrq)
0.06%
Levered Free Cash Flow (ttm)
-21.16M